Risperidone Effects in Treatment-Resistant Adolescents: Preliminary Case Reports
The DOI matches its Crossref record.
Abstract
Many children and adolescents with a variety of chronic psychiatric disorders receive long-term therapy with antipsychotic medications. Clinical case reports are presented of seven such adolescents, aged 11–17 years, who were treated with risperidone. All but one patient had prior unsuccessful treatments with various psychotropic medications. The use of risperidone seemed effective in six of the seven adolescents in a dose range of 1–4 mg daily, with a significant therapeutic response appearing in 1 to 3 weeks. The length of risperidone treatment ranged from 3 to 15 months. Some sedation/drowsiness was observed in two patients at the maximum recommended adult dose (6 mg/day), but this was resolved by a reduction in the daily dosage. There were no other significant adverse effects, including extrapyramidal reactions. Two adolescents received concomitant medication, including d-amphetamine and clomipramine. Risperidone appeared to be effective in relieving a variety of symptoms across a range of diagnoses, including schizophrenia, pervasive developmental disorder (PDD), and attention deficit disorder (ADD), but not obsessive compulsive disorder (OCD). Risperidone administration seemed most useful in treating paranoid ideation, aggressive and impulsive behavior, and mood swings. Controlled studies are needed to determine the efficacy and safety of risperidone in adolescents. If risperidone proves to be safe and effective over the long term, then clinicians may have a relatively nontoxic "antipsychotic" agent that could relieve disabling symptoms in nonpsychotic as well as psychotic children and adolescents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Risperidone Disruptive Behavior Study Group (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1337 · Cited by 475
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia
McClellan, J., & Stock, S. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.02.008 · Cited by 361
Second-Generation Antipsychotic Medications in Children and Adolescents
Cheng-Shannon, J., McGough, J. J., Pataki, C., & McCracken, J. T. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.372 · Cited by 152
Antipsychotics in Children and Adolescents
CAMPBELL, M., RAPOPORT, J. L., & SIMPSON, G. M. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199905000-00015 · Cited by 113
Metadata
- Authors
- SIMEON, J. G., CARREY, N. J., WIGGINS, D. M., MILIN, R. P., & HOSENBOCUS, S. N.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1995-01
- Volume
- 5
- Issue
- 1
- Pages
- 69-79
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2011936103
- Cited by
- 53
- References
- 0
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risperidone Effects in Treatment-Resistant Adolescents: Preliminary Case Reports. https://app.cochat.ai/papers/10.1089/cap.1995.5.69
- The paper
- SIMEON, J. G., CARREY, N. J., WIGGINS, D. M., MILIN, R. P., & HOSENBOCUS, S. N. (1995). Risperidone Effects in Treatment-Resistant Adolescents: Preliminary Case Reports. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.1995.5.69
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.